Brooke Towne, MD
Interventional Pain Medicine · Oceanside, CANPI 1225532039
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,501 of the $11,158 with a category attached, or 76.2%. 32 manufacturers reported payments, led by Abbott at 33.6% of the total. Reporting peaked in 2023 at $4,909 and has fallen 62.4% since, to $1,846 in 2025.
Across 273 payments — averaging $40.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Boston Scientific$2K
- Saluda Medical Americas, Inc.$914
- Medtronic$738
- Collegium Pharmaceutical, Inc.$518
- SPR Therapeutics, Inc$459
- plus $3K from 26 others
What the payments were for
- Travel & lodging$2,65624%
- Food & beverage$8,50176%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 64 | $3,747 |
| Boston Scientific | 32 | $2,102 |
| Saluda Medical Americas, Inc. | 20 | $914 |
| Medtronic | 14 | $738 |
| Collegium Pharmaceutical, Inc. | 34 | $518 |
| SPR Therapeutics, Inc | 7 | $459 |
| Nalu Medical, Inc. | 30 | $367 |
| Nevro Corp. | 4 | $334 |
| Curonix LLC | 14 | $325 |
| MML US, Inc. | 3 | $199 |
| AbbVie | 6 | $153 |
| Virtus Pharmaceuticals LLC | 7 | $147 |
| Bioventus LLC | 1 | $139 |
| Vertex | 5 | $132 |
| Tersera Therapeutics LLC | 4 | $126 |
| Merz Pharmaceuticals, LLC | 1 | $114 |
| Painteq LLC | 4 | $97 |
| Vertos Medical, Inc. | 3 | $92 |
| Si-bone, Inc. | 3 | $84 |
| Pfizer | 3 | $53 |
| Scilex Pharmaceuticals Inc. | 2 | $49 |
| Johnson & Johnson | 1 | $40 |
| Stryker | 1 | $35 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Averitas Pharma Inc. | 1 | $25 |
| Impel Pharmaceuticals LLC | 1 | $24 |
| Spinal Simplicity, LLC | 1 | $23 |
| Fidia Pharma USA Inc. | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $18 |
| Zimmer Biomet | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$1,643
- INTELLIS ADAPTIVESTIM$319
- Evoke$299
- SPRINT PNS System$293
- Senza$216
- ReActiv8$165
- WaveWriter Alpha Prime 16$157
- Superion Indirect Decompression System$144
- Stimrouter Implantable Kit$139
- Evoke SCS$137
- XEOMIN$114
- Omnia$100
- ETERNA$100
How this compares
$11,158 in reported general payments places this provider in the 75th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 66 | $36,033 |
| Nucynta ErTapentadol Hcl | 14 | $21,923 |
| Xtampza ErOxycodone Myristate | 26 | $12,268 |
| HorizantGabapentin Enacarbil | 13 | $9,592 |
| Buprenorphine | 30 | $7,633 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 205 | $4,511 |
| Lidocaine | 52 | $4,003 |
| Pregabalin | 150 | $3,133 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 82 | $2,958 |
| Fentanyl | 40 | $2,945 |
| Celecoxib | 105 | $1,489 |
| Hydromorphone ErHydromorphone Hcl | 13 | $1,223 |
| Oxycodone Hcl | 92 | $1,213 |
| Gabapentin | 132 | $1,115 |
| Tramadol Hcl | 49 | $841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Xtampza Er | $518 | $70,224106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 188 interventional pain medicine providers in California.
Other interventional pain medicine in Oceanside
- Michael Verdolinla Mesa$507K
- Tim LeierRancho Mirage$449K
- Jonathan GrossmanVisalia$404K
- Kasra MaasumiRancho Santa Margarita$388K
- Andrew GermanovichRancho Mirage$333K
- David LeeYorba Linda$257K
- Standiford HelmOrange$254K
- Patrick BuchananCamarillo$219K
- Chau VuSanta Rosa$141K
- Phillip LimBuena Park$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.